药事管理与临床药学系崔一民团队和药物化学系刘振明团队发现靶向整合素受体的前列腺癌潜在新疗法

中国药学(英文版) ›› 2023, Vol. 32 ›› Issue (2): 158-161.

药事管理与临床药学系崔一民团队和药物化学系刘振明团队发现靶向整合素受体的前列腺癌潜在新疗法

北京大学药学院

北京大学药学院

收稿日期:2023-02-15 修回日期:2023-02-16 接受日期:2023-02-16 出版日期:2023-02-28 发布日期:2023-03-06

The teams of Prof. Yimin Cui and Prof. Zhenming Liu have discovered a potential new treatment for castration-resistant prostate cancer that targets integrin receptors

School of Pharmaceutical Sciences, Peking University Health Science Center

School of Pharmaceutical Sciences, Peking University Health Science Center

Received:2023-02-15 Revised:2023-02-16 Accepted:2023-02-16 Online:2023-02-28 Published:2023-03-06

摘要/Abstract

摘要：

2023年2月10日, 北京大学药学院药事管理与临床药学系崔一民教授团队和药物化学系刘振明研究员团队合作在Nature子刊Signal Transduction and Targeted Therapy杂志(Q1区, IF = 38.104)在线发表了题为“Discovery of C19-9 as a novel non-RGD inhibitor of αvβ3 to overcome enzalutamide resistance in castration-resistant prostate cancer”的研究论文, 该研究发现了一类新型整合素受体抑制剂, 有望成为克服恩杂鲁胺耐药的前列腺癌新疗法。

Supporting:

北京大学药学院. 药事管理与临床药学系崔一民团队和药物化学系刘振明团队发现靶向整合素受体的前列腺癌潜在新疗法[J]. 中国药学(英文版), 2023, 32(2): 158-161.

School of Pharmaceutical Sciences, Peking University Health Science Center. The teams of Prof. Yimin Cui and Prof. Zhenming Liu have discovered a potential new treatment for castration-resistant prostate cancer that targets integrin receptors[J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(2): 158-161.